Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Japan’s Sosei Group will spend $45 million to acquire a 25.6% ownership stake in MiNA Therapeutics and an option to potentially acquire all of the London-based firm. MiNA’s lead compound is MTL-CEBPA, a small activating RNA that is in the midst of Phase I/IIa clinical trials as an advanced liver cancer treatment. Sosei says MiNA will complement Heptares Therapeutics, a London-based developer of drugs targeting G protein-coupled receptors that Sosei acquired in 2015.
This article has been sent to the following recipient: